Dr Lalchandani Labs Ltd
Incorporated in 2011, Dr. Lalchandani Labs Ltd is in the business of running laboratories
for pathological investigations[1]
- Market Cap ₹ 8.58 Cr.
- Current Price ₹ 19.8
- High / Low ₹ 35.0 / 15.7
- Stock P/E
- Book Value ₹ 20.4
- Dividend Yield 0.00 %
- ROCE -3.68 %
- ROE -16.1 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.97 times its book value
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of 1.32% over last 3 years.
- Company has high debtors of 360 days.
- Working capital days have increased from 181 days to 288 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|
2.79 | 5.26 | 6.10 | 9.78 | 11.28 | 5.04 | 5.49 | |
2.17 | 4.06 | 4.84 | 7.54 | 8.81 | 4.95 | 4.88 | |
Operating Profit | 0.62 | 1.20 | 1.26 | 2.24 | 2.47 | 0.09 | 0.61 |
OPM % | 22.22% | 22.81% | 20.66% | 22.90% | 21.90% | 1.79% | 11.11% |
0.03 | 0.01 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | |
Interest | 0.16 | 0.14 | 0.18 | 0.35 | 0.60 | 0.99 | 0.62 |
Depreciation | 0.13 | 0.35 | 0.42 | 0.52 | 0.59 | 0.66 | 0.67 |
Profit before tax | 0.36 | 0.72 | 0.66 | 1.37 | 1.28 | -1.56 | -0.68 |
Tax % | 25.00% | 26.39% | 28.79% | 26.28% | 28.12% | -0.00% | |
0.26 | 0.53 | 0.47 | 1.01 | 0.93 | -1.56 | -0.68 | |
EPS in Rs | 0.89 | 1.22 | 1.08 | 2.33 | 2.15 | -3.60 | -1.57 |
Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 13% |
3 Years: | -6% |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 38% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 0% |
3 Years: | -7% |
1 Year: | -27% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 3% |
3 Years: | 1% |
Last Year: | -16% |
Balance Sheet
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|
Equity Capital | 2.93 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 |
Reserves | 0.40 | 3.73 | 4.21 | 5.22 | 6.15 | 4.59 | 4.50 |
1.88 | 0.90 | 1.76 | 4.04 | 5.15 | 6.40 | 6.29 | |
1.00 | 1.18 | 1.63 | 1.61 | 2.49 | 2.40 | 2.03 | |
Total Liabilities | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 17.15 |
2.06 | 3.28 | 3.47 | 5.24 | 5.75 | 5.39 | 5.06 | |
CWIP | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
Investments | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 |
3.91 | 6.62 | 8.22 | 9.72 | 12.13 | 12.09 | 11.85 | |
Total Assets | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 17.15 |
Cash Flows
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|
0.58 | -0.45 | -0.10 | 1.19 | 2.01 | -0.00 | |
-1.29 | -1.95 | -0.53 | -2.26 | -1.53 | -0.20 | |
1.57 | 3.51 | 0.85 | 1.71 | 0.16 | -0.23 | |
Net Cash Flow | 0.85 | 1.12 | 0.23 | 0.64 | 0.64 | -0.43 |
Ratios
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|
Debtor Days | 149.14 | 126.99 | 199.25 | 148.54 | 136.55 | 359.93 |
Inventory Days | 167.03 | 233.36 | 158.70 | 68.75 | 191.07 | 458.51 |
Days Payable | 426.86 | 406.89 | 355.48 | 97.06 | 175.15 | 404.21 |
Cash Conversion Cycle | -110.69 | -46.54 | 2.47 | 120.23 | 152.47 | 414.23 |
Working Capital Days | 168.76 | 170.70 | 209.43 | 132.86 | 123.93 | 287.51 |
ROCE % | 12.14% | 8.72% | 14.40% | 12.87% | -3.68% |
Documents
Announcements
- Appointment of Company Secretary and Compliance Officer 2 May
-
Compliance Certificate Under Regulation 40(10) Of SEBI (LODR) Regulations, 2015
20 Apr - Compliance certificate under Reg 40(10) for the quarter ended March 2024
- Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations For The Year Ended March 2024 17 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Apr - Certificate by RTA under Reg 74(5) for the quarter ended March, 2024
- Reply To The Clarification Sought Dated April 09, 2024 10 Apr
Business Overview:[1][2][3]
DLLL is a NABL accredited company with 5 Self-sufficient Labs and 15 collection centers across Delhi/NCR. It is empaneled for CGHS (South, North and East Block), DJB, MCD, DDA etc. and provides diagnostic and related healthcare tests and services. Company owns, runs laboratories for carrying out pathological investigations of various branches of Bio-Chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Virology, Cytology, other pathological Investigations and Immunoassay, Immuno-Histochemistry, Molecular Pathology, DNA & Genetic Testing etc.